1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Cancer Drug News 15 FEBRUARY 2016

Cancer Drug News 15 FEBRUARY 2016

  • February 2016
  • -
  • Espicom Business Intelligence
  • -
  • 12 pages

Industry Trend Analysis - Ownership Of Digital Reputation Crucial With Growing Compassionate Use Demand
Industry Brief - Amgen's Kyprolis In Combination Now Available In UK To Treat Relapsed MM
Industry Brief - Incyte To Discontinue Phase III Study Of Jakafi Plus Capecitabine In MPC
Industry Trend Analysis - European Alimta Threats Will Place Further Pressure On Lilly
Industry Brief - IDMC Recommends Stopping Alecensa Phase III Trial Early After Positive Outcomes
Industry Brief - Ferring Initiates Phase IIIb Trial Of Degarelix ADT Therapy In Advanced PCA And CVD
Industry Trend Analysis - Combination Approach Increases Commercial Scope For Small Oncolytic Immunotherapy Developers
Industry Brief - Lannett Gains Temozolomide Approval
Industry Brief - Enrolment Begins In Melphalan/HDS System Phase III Trial In Hepatic Dominant OM
Industry Brief - Adaptimmune's NY-ESO T-Cell Therapy Granted Breakthrough Therapy Designation
Industry Brief - Tollys Secures Rights To Riboxx' Apoxxim For TLR3-Positive Cancers
Industry Brief - Epizyme's Tazemetostat Gains Orphan Drug Designation For MRTs
Industry Brief - EMA Accepts Sandoz' Biosimilar Pegfilgrastim Submission
Industry Trend Analysis - Expanded Injectable Approval Will Not Maintain Emend's Market Position
Industry Brief - OncoGenex To Reduce Workforce

Table Of Contents

Cancer Drug News 15 FEBRUARY 2016

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Ulcerative Colitis: KOL Insight

Ulcerative Colitis: KOL Insight

  • $ 8085
  • Industry report
  • September 2016
  • by Firstword Pharma

Are UC biosimilars a real or perceived threat to branded drugs? Ulcerative colitis (UC) treatment is on the brink. Patents are ending on various branded drugs and clearing the way for an influx of biosimilars; ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Hepatitis C: Kol Insight

September 2016 $ 8085

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.